Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			ATTY, DOCKET NO. INTERNATIONAL A			PPLICATION NO.			
IN	FORM	ATION DISCLOSE BY APPLICAL	P &		APPLICANT Douglas Nesta	<b></b> _					
AUG 2 6 2005					PRIORITY FILING DATE 2 July 2002  GROUP  GROUP  1644						
		Document	DENA U.S. PATE	NT DC	CUMENTS	<del></del>					
Examiner Initial		Document Number	Date	Name		Clas	s Subclass	Filing Date If Appropriate			
/MD/	AA	6,171,586	9 Jan. 2001	Lam	, et al.				<del></del>		
									***************************************		
1											
			FOREIGN PA	ATENT	DOCUMENTS						
		Document Number	Date			Clas	s Subclass	<u>Translation</u> Yes ! No			
/MD/	BA	WO97/04801	13 Feb. 1997	PCT							
									<del>,</del>		
								-			
		OTHER DOCU	MENTS (Including	Autho	r, Title, Date, Pertinent P	Pages, Fta	2.)		I		
	CA				, SmithKline Beecha			ND," R	& <i>D</i>		
Focus Drug News (October 4, 1999) W					Vorld Publications Ltd., ISSN: 1350-1135						
/MD/	СВ	Smith, S., "Technology Evaluation: C242-DM1, ImmunoGen Inc.," Current Opinion in Molecular Therapeutics (2001) 3(2):198-203 (XP-008011026.)									
									· .		
		<del></del>		<del>-</del>		- <del> </del>					
EXAMINER /Marianne Dibrino/				DATE CONSIDERED 05/03/2007							
					on is in conformance w copyof this form with ne						

Sheet <u>1</u> of <u>1</u>.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			ATTY, DOCKET NO. P51355	1	INTERNATIONAL APPLICATION NO. PCT/US03/20751			
INFORMATION DISCLOSURE STATEMENT					APPLICANT 10/51903					
BY APPLICANT					Douglas P. NESTA					
			FIUNG DATE GROUP							
	(U	se several sheets if ı	Herewith		1644					
			U.	.S. PATENT I	DOCUMENTS					
Examiner Initial		Document Number	Date		Name	Class	Subclass	Filing Date If Appropriate		
	AA									
					<del> </del>					
<u> </u>										
			FORI	EIGN PATEN	NT DOCUMENTS			<b>'</b>	-	
		Document Date . Number		Country	Class	s Subclass <u>Translati</u> Yes I		ilation No		
	<u> </u>	OTHER DOC	LUMENTS (Inc.	Cluding Auti	hor Title Date Perline	ot Pages F	(fc.)		<u> </u>	
/MD/	CA	"Cantuzumab Mertansine ImmunoGen, SmithKline Beecham US FDA accepts IND," R&D Focus Drug News (October 4, 1999) World Publications Ltd., ISSN: 1350-1135								
EXAMINER		/Marianne Dibrino/			DATE CONSIDERED 05/03/2007					